Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Literature DB >> 16870779

Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Emilia Cantón¹, Javier Pemán, Macrina Sastre, Mónica Romero, Ana Espinel-Ingroff.

Abstract

Amphotericin B (AMB), micafungin, and caspofungin MICs, minimal fungicidal concentrations, and time-killing curves were determined in the presence and absence of 10% inactivated serum. AMB was the only agent with consistent killing activity (time required to achieve 99.9% of growth reduction was 2.1 to 3.2 h). The presence of serum enhanced caspofungin activity but lowered those of micafungin and AMB.

Entities: Chemical Species

Mesh：

Substances：

Year: 2006 PMID： 16870779 PMCID： PMC1538680 DOI： 10.1128/AAC.00524-06

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

23 in total

1. Case report. Osteomyelitis caused by high resistant Candida guilliermondii.

Authors: H J Tietz; V Czaika; W Sterry
Journal: Mycoses Date: 1999 Impact factor: 4.377

2. [Study of in vitro activity of caspofungin on non-Candida albicans yeast strains determined by two methods: M27-A2 and EUCAST].

Authors: M Romero; E Cantón; J Pemán; M Gobernado
Journal: Rev Esp Quimioter Date: 2004-09 Impact factor: 1.553

3. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii.

Authors: J D Dick; B R Rosengard; W G Merz; R K Stuart; G M Hutchins; R Saral
Journal: Ann Intern Med Date: 1985-01 Impact factor: 25.391

4. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors: K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191

5. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors: R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191

6. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors: A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal: J Clin Microbiol Date: 2000-09 Impact factor: 5.948

Review 7. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors: V Krcmery; A J Barnes
Journal: J Hosp Infect Date: 2002-04 Impact factor: 3.926

8. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.

Authors: T Chiller; K Farrokhshad; E Brummer; D A Stevens
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

9. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors: S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal: Antimicrob Agents Chemother Date: 2000-01 Impact factor: 5.191

10. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

Authors: M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal: Diagn Microbiol Infect Dis Date: 2004-02 Impact factor: 2.803

12 in total

Review 1. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors: Natalie J Carter; Gillian M Keating
Journal: Paediatr Drugs Date: 2009 Impact factor: 3.022

Review 2. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors: Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal: Intensive Care Med Date: 2014-08-05 Impact factor: 17.440

3. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

Authors: Emilia Cantón; Ana Espinel-Ingroff; Javier Pemán; Lucas del Castillo
Journal: Antimicrob Agents Chemother Date: 2010-02-09 Impact factor: 5.191

4. Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates.

Authors: Ana Espinel-Ingroff; E Canton; J Peman; E Martín-Mazuelo
Journal: Antimicrob Agents Chemother Date: 2009-12-22 Impact factor: 5.191

5. Fungal echinocandin resistance.

Authors: Carol A Munro
Journal: F1000 Biol Rep Date: 2010-09-08

Review 6. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

Authors: Sarah A Cross; Lesley J Scott
Journal: Drugs Date: 2008 Impact factor: 9.546

7. Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi, and vaginal Lactobacillus by 3-O-octyl-sn-glycerol.

Authors: B J Moncla; K Pryke; Charles E Isaacs
Journal: Antimicrob Agents Chemother Date: 2008-01-28 Impact factor: 5.191

8. Elevated chitin content reduces the susceptibility of Candida species to caspofungin.

Authors: Louise A Walker; Neil A R Gow; Carol A Munro
Journal: Antimicrob Agents Chemother Date: 2012-10-22 Impact factor: 5.191

9. Fungal echinocandin resistance.

Authors: Louise A Walker; Neil A R Gow; Carol A Munro
Journal: Fungal Genet Biol Date: 2009-09-19 Impact factor: 3.495

Review 10. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.

Authors: Claudia Spampinato; Darío Leonardi
Journal: Biomed Res Int Date: 2013-06-26 Impact factor: 3.411